A share price of Bicycle Therapeutics Plc ADR [BCYC] is currently trading at $25.29, up 3.78%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCYC shares have gain 3.18% over the last week, with a monthly amount glided 29.16%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on September 11, 2023, when B. Riley Securities upgraded its rating to a Buy. On July 28, 2022, Barclays initiated with a Overweight rating and assigned a price target of $30 on the stock. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $33 on April 13, 2022. In a note dated February 14, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $60 on this stock.
Bicycle Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $12.54 and $27.24. Currently, Wall Street analysts expect the stock to reach $70.5 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $25.29 at the most recent close of the market. An investor can expect a potential return of 178.77% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
Trailing Twelve Months sales for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] were 41.65M which represents 295.08% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -4.7%, Pretax Profit Margin comes in at -4.37%, and Net Profit Margin reading is -4.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.49 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.76 points at the first support level, and at 20.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.77, and for the 2nd resistance point, it is at 28.24.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] is 10.42. Further, the Quick Ratio stands at 10.42, while the Cash Ratio is 9.23. Considering the valuation of this stock, the price to sales ratio is 25.89, the price to book ratio is 3.03.
Transactions by insiders
Recent insider trading involved Lee Kevin, CHIEF EXECUTIVE OFFICER, that happened on Jul 03 ’24 when 3194.0 shares were sold. CHIEF TECHNOLOGY OFFICER, Skynner Michael completed a deal on Jul 03 ’24 to sell 967.0 shares. Meanwhile, CHIEF OPERATING OFFICER Milnes Alistair sold 967.0 shares on Jul 03 ’24.
